A Cleavage Enzyme-Cytometric Bead Array Provides Biochemical Profiling of Resistance Mutations in HIV-1 Gag and Protease

被引:10
作者
Breuer, Sebastian [1 ]
Sepulveda, Homero [2 ]
Chen, Yu [2 ]
Trotter, Joseph [2 ]
Torbett, Bruce E. [1 ]
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] BD Biosci, San Diego, CA 92121 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; PROCESSING SITES; DRUG-RESISTANCE; VIRAL FITNESS; AMINO-ACID; IN-VIVO; INHIBITORS; VARIANTS; POLYMORPHISM; SELECTION;
D O I
10.1021/bi200031m
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most protease-substrate assays rely on short, synthetic peptide substrates consisting of native or modified cleavage sequences. These assays are inadequate for interrogating the contribution of native substrate structure distal to a cleavage site that influences enzymatic cleavage or for inhibitor screening of native substrates. Recent evidence from HIV-1 isolates obtained from individuals resistant to protease inhibitors has demonstrated that mutations distal to or surrounding the protease cleavage sites in the Gag substrate contribute to inhibitor resistance. We have developed a protease substrate cleavage assay, termed the cleavage enzyme cytometric bead array (CE-CBA), which relies on native domains of the Gag substrate containing embedded cleavage sites. The Gag substrate is expressed as a fluorescent reporter fusion protein, and substrate cleavage can be followed through the loss of fluorescence utilizing flow cytometry. The CE-CBA allows precise determination of alterations in protease catalytic efficiency (k(cat)/K(M)) imparted by protease inhibitor resistance mutations in protease and/or gag in cleavage or noncleavage site locations in the Gag substrate. We show that the CE-CBA platform can identify HIV-1 protease present in cellular extractions and facilitates the identification of small molecule inhibitors of protease or its substrate Gag. Moreover, the CE-CBA can be readily adapted to any enzyme substrate pair and can be utilized to rapidly provide assessment of catalytic efficiency as well as systematically screen for inhibitors of enzymatic processing of substrate.
引用
收藏
页码:4371 / 4381
页数:11
相关论文
共 40 条
[1]  
Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
[2]   Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors [J].
Bally, F ;
Martinez, R ;
Peters, S ;
Sudre, P ;
Telenti, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) :1209-1213
[3]   Viral evolution in response to the broad-based retroviral protease inhibitor TL-3 [J].
Bühler, B ;
Lin, YC ;
Morris, G ;
Olson, AJ ;
Wong, CH ;
Richman, DD ;
Elder, JH ;
Torbett, BE .
JOURNAL OF VIROLOGY, 2001, 75 (19) :9502-9508
[4]   Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens [J].
Colonno, R ;
Rose, R ;
McLaren, C ;
Thiry, A ;
Parkin, N ;
Friborg, J .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (10) :1802-1810
[5]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[6]   Mechanistic considerations in high-throughput screening [J].
Copeland, RA .
ANALYTICAL BIOCHEMISTRY, 2003, 320 (01) :1-12
[7]   Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss [J].
Dam, Elisabeth ;
Quercia, Romina ;
Glass, Baerbel ;
Descamps, Diane ;
Launay, Odile ;
Duval, Xavier ;
Kraeusslich, Hans-Georg ;
Hance, Allan J. ;
Clavel, Francois .
PLOS PATHOGENS, 2009, 5 (03)
[8]   Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors [J].
Doyon, L ;
Croteau, G ;
Thibeault, D ;
Poulin, F ;
Pilote, L ;
Lamarre, D .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3763-3769
[9]  
DUNN BM, 1994, METHOD ENZYMOL, V241, P254
[10]   Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites [J].
Fehér, A ;
Weber, IT ;
Bagossi, P ;
Boross, P ;
Mahalingam, B ;
Louis, JM ;
Copeland, TD ;
Torshin, IY ;
Harrison, RW ;
Tözsér, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (16) :4114-4120